AbbVie reports improved patient satisfaction with aesthetic treatment after medical weight loss
ABBV•AbbVie’s Allergan Aesthetics will present nine abstracts at a dermatologic surgery meeting in San Diego. Two Phase 4 studies found improved appearance satisfaction and psychosocial function among patients using GLP-1-related weight-loss medications; an imaging analysis found similar outcomes with investigational trenibotE and Botox Cosmetic.
1. Conference findings
AbbVie’s Allergan Aesthetics will present nine abstracts at the American Society for Dermatologic Surgery meeting, Nov. 5-8, 2026, in San Diego. Two Phase 4 studies examine aesthetic treatments in patients using GLP-1-related weight-loss medications, with findings showing improved appearance satisfaction and psychosocial function. A digital imaging analysis found similar glabellar line and brow position outcomes with investigational trenibotE versus Botox Cosmetic; it is scheduled for Nov. 8 at 7:30 a.m. PT.
